Adoptive T Cell Therapy (TIL)
(Read more)
IOV-GM1-201 - A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Summary: NSCLC and Melanoma Adoptive T cell Therapy
Read more on NCI
Advanced Solid Tumors
(Read more)
Arcus Protocol AB680CSP00902 - A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies tumors
Summary: This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.
Condition/Disease: Pancreatic Cancer
Read more on NCI
(Read more)
AstraZeneca Protocol D8151C00001 - A phase II study to evaluate the safety, pharmaco kinetics, and clinical activity of AZD0171 in combination with durvalumab and chemotherapy in participants with locally advanced or metastatic solid tumors
Summary: The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
Condition/Disease: Advanced Solid Tumors, Phase I Clinical Trials
Read more on NCI
(Read more)
AVZO-1418-1001 - A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors
Summary: This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.
Read more on NCI
(Read more)
BDTX-4933-101/TACRI - A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
Summary: BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase.
Read more on NCI
(Read more)
Bioatla Protocol BA3071-001 - A phase ½ study of BA3071 in combination with NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Summary: The objective of this study is to assess safety and efficacy of BA3071 in solid tumors.
Condition/Disease: Advanced Solid Tumors, Phase I Clinical Trials
Read more on NCI
(Read more)
CA2360001 - A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
Summary: The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Read more on NCI
(Read more)
CORT125236-750 - A Phase 1b/2, Open-Label, Dose-Finding and Proof of Concept Study of Nenocorilant in Combination With Anti-Programmed Cell Death/(Ligand) 1 in Patients With Advanced Solid Malignancies
Summary: This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
Read more on NCI
(Read more)
CP-MGC026-01 - A Study of MGC026 in Participants With Advanced Solid Tumors
Summary: SCCHN, esophageal squamous cell carcinoma, squamous and non-squamous NSCLC, SCLC, bladder cancer, sarcoma, endometrial cancer, melanoma, castration-resistant prostate cancer, breast cancer, ovarian cancer, cervical cancer, colorectal cancer, gastric/GEJ cancer, pancreaticcarcinoma, clear cell RCC, or HCC
Read more on NCI
(Read more)
CRB-601-01 - First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor
Summary: Part A: All histological types of the following tumors: endometrial, ovarian, cervical, NSCLC, RCC, HNSCC, melanoma, HCC and TNBC, and in agreement
with the Sponsor, participants with, esophageal, gastric, and urothelial cancer may be enrolled. Other solid tumor types may be enrolled on agreement with the
Sponsor.
Part B: Endometrial, ovarian, cervical, NSCLC, RCC, HNSCC, melanoma, HCC and TNBC. Part C: To be defined pending data
Read more on NCI
(Read more)
DB-1311-201 - A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors
Summary: A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Read more on NCI
(Read more)
DB-1317-101 - A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants With Selected Advanced/Metastatic Solid Tumors
Summary: This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes one randomized dose expansion cohort and two single-arm dose expansion cohorts to further evaluate the safety, tolerability and preliminary efficacy of DB-1317 in selected solid tumors and to identify optimal RP2D.
Read more on NCI
(Read more)
DF6215-001 - Study of DF6215 in Patients with Advanced Solid Tumors
Summary: (1) melanoma dose enrichment cohort open (75ug/kg q2wk); (2) dragonfly (IL2) combo with pembro – all solid tumors.
Also melanoma monotherapy slots available; Escalation cohorts allow all refractory tumor types
Read more on NCI
(Read more)
EAY191 - N5 - Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Summary: OPEN. Patients must have a HER2 amplified solid tumor except breast cancer. Patient’s cancer must have HER2 amplification as defined with ≥ 7 copies by NGS testing. Patients must have recurrent or persistent disease. No known evidence of RB1 loss or deletion including copy number loss or deleterious mutation. *Refer to protocol for eligibility criteria
Read more on NCI
(Read more)
Endocrine Marker - Prospective study of predictive markers and changes in specific endocrine hormones in patients with metastatic cancers treated with immune checkpoint inhibitors
(Read more)
Exelixis Protocol XL184-021 - A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
Summary: This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.
(Read more)
GIM531-CT01 - Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Summary: NSCLC, TNBC, Ovarian Cancer, AKT3 mutation, Melanoma
Read more on NCI
(Read more)
GSK Protocol 212214 - A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors
Summary: This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. In addition, dostarlimab will be given as monotherapy and in combination with GSK6097608 and with GSK4428859A (EOS884448) in Japanese and Chinese participants. Drug name mentioned as GSK4428859A and EOS884448 are interchangeable for the same compound. In the rest of the document, the drug will be referred to as GSK4428859A (EOS884448).
Condition/Disease: Endometrial Cancer
Read more on NCI
(Read more)
GV20-0251-100 - A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Summary: Pre-Treated Cutaneous melanoma (Part B Cohort 3 or Part C Backfill)
Read more on NCI
(Read more)
IDE161-001 - A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Summary: Endometrial only at this time
Read more on NCI
(Read more)
Immunocore Protocol IMC-C103-101 - A phase ½ first-in-human study of the safety and efficacy of IMC-C103C as a single agent and in combination with atezolizumab in HLA-A 0201-positive patients with advanced mage-A4- positive cancer
Summary: IMC-C103C is an immune mobilizing T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for MAGE-A4.
The IMC-C103C-101 Phase 1/2 study will be evaluated in patients with metastatic/unresectable tumors which include select Advanced Solid Tumors and will be conducted in two phases.
1. To identify the MTD and/or RP2D of IMC-C103C as a single agent administered Q1W (Arm A1) and administered Q1W in combination with Q3W atezolizumab (Arm A2).
2. To assess the preliminary anti-tumor activity of IMC C103C in one or more selected indications, as a single agent administered Q1W (Arm B1) and administered Q1W in combination with Q3W atezolizumab (Arm B2).
(Read more)
INCA 33890-101 - A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Summary: NSCLC pretreated (no slots unless screeen fail) , ovarian (no slots unless screeen fail), MSS-CRC in combinations with chemotherapy for 1st line ( Slots availabe), 2nd line after oxaliplatin (slots avialable) or up to 4 lines (no slots available)
Read more on NCI
(Read more)
Incyte Protocol INCA32459-101 - Incyte LAG3xPD-1 study - A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies
Condition/Disease: Advanced Solid Tumors
(Read more)
KIN-2787 - A Study to Evaluate KIN-2787 in Participants with BRAF And/ or NRAS Mutation Positive Solid Tumors
Summary: Dose escalation and expansion study in participants with BRAF mutation-positive and/or NRAS mutation-positive tumors designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of KIN-2787, a RAF small molecule kinase inhibitor, to determine a recommended Phase 2 dose (RP2D) of KIN-2787
Read more on NCI
(Read more)
MRNA-4359-P101 - Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Summary: The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
Read more on NCI
(Read more)
NGM Bio Protocol 831-IO-101 - A Phase 1/1b dose escalation /expansion study of NGM831 as monotherapy and in combination with pembrolizumab in advanced or metastatic solid tumors
Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors.
Condition/Disease: Advanced Solid Tumors, Ovarian Cancer, Gastric Cancer, Melanoma - Metastatic Melanoma, Pancreatic Cancer, Phase I Clinical Trials, Head and Neck Cancer, Lung Cancer - Non-Small Cell, Renal Cell Carcinoma
Read more on NCI
(Read more)
OBX115-23-01 - Safety and Efficacy of OBX-115 in Advanced Solid Tumors (Agni-01)
Summary: TIL therapy for NSCLC and Melanoma ; No melanoma slots, NSCLC availlable (no driver mutations except KRAS)
Read more on NCI
(Read more)
PF-08046031 - A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Summary: Antibody Drug Conjugate (ADC) n pretreated cutaneous melanoma
Read more on NCI
(Read more)
SMP-3124-101 - An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors
Summary: An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Read more on NCI
(Read more)
SNV4818-101 - A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors
Summary: This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.
Read more on NCI
(Read more)
SWOG 2101 - Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers – an immunoMATCH Pilot Study
Summary: HNSCC & Melanoma HEAVY PRETREATED
Condition/Disease: Melanoma
Read more on NCI
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
(Read more)
TV56278-ONC-10203 - A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination With Pembrolizumab in Participants With Selected Locally Advanced or Metastatic Solid Tumors
Summary: The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Determine a RP2D of TEV-56278 in combination with pembrolizumab The secondary objectives of this trial are to: * Characterize the serum pharmacokinetics of TEV-56278 * Evaluate the antitumor activity of TEV-56278 * Determine the safety and tolerability of TEV-56278 * Evaluate other measures of antitumor activity of TEV-56278 * Evaluate anti-tumor activity Participants will be treated up to 12 months with a follow-up period of up to 12 months after last infusion. The total duration of the trial will be up to 25 months for individual participants.
Read more on NCI
Breast Cancer
(Read more)
S2206 - Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Summary: This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy.
Read more on NCI
Common
(Read more)
Astellas Protocol 8951-CL-0103 - A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression
Summary: The purpose of this study is to determine the Objective Response Rate (ORR) of zolbetuzimab as a single agent as assessed by an independent central reader. This study will also assess the ORR and Progression Free Survival (PFS) of zolbetuximab in combination with mFOLFOX6 (with or without Nivolumab) and in combination with pembrolizumab, assess the safety and tolerability, assess the effects on CLDN18.2 expression and assess the immunogenicity and immunomodulatory effects of zolbetuximab as a single agent and in combination with mFOLFOX6 (with or without Nivolumab) and in combination with pembrolizumab. This study will also evaluate the pharmacokinetics (PK) of zolbetuximab, oxaliplatin, fluorouracil (5-FU), and pembrolizumab, evaluate health-Related Quality of Life (HRQoL), evaluate the Disease Control Rate (DCR), Duration of Response (DOR), PFS of zolbetuximab as a single agent, in combination with mFOLFOX6 (with or without Nivolumab) and in combination with pembrolizumab based on both investigator and independent central reader assessment, assess Overall Survival (OS) of zolbetuximab as a single agent and in combination with pembrolizumab.
Condition/Disease: Gastric Cancer
Read more on NCI
(Read more)
EIIT2022-S22-00325 - Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Summary: First Line Melanoma (nonUveal) LAG/PD1/CTLA4
Read more on NCI
(Read more)
TAPUR - Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
Summary: https://cdn.bfldr.com/KOIHB2Q3/as/39tsg65qhf362fx5fqfskp/TAPUR-Cohort-Report
Condition/Disease: Advanced Cancer
Read more on NCI
Head & Neck Cancer (HNSCC)
(Read more)
R3767-ONC-2431 - Phase II Randomized Study of Fianlimab Plus Cemiplimab Versus Cemiplimab Plus Placebo in First-Line Treatment of Participants With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Is Positive for PD-L1 Expression
Summary: This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form. The study is focused on participants with head and neck cancers who have not been previously treated for head and neck cancer that has come back or spread to other parts of the body, referred to as recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Read more on NCI
Immunotherapy & ImmunoOncology
(Read more)
MRNA-4359-P101 - Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Summary: The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.
Read more on NCI
Lung Cancer
(Read more)
mRNA-4157-P101 - Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603)
Summary: Neo-Adjuvant Lung and Neo-Adjuvant Gastric Cancer
Condition/Disease: Gastric Cancer
Read more on NCI
Melanoma
(Read more)
MCC21341 - A Phase II Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Summary: The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.
Read more on NCI
(Read more)
Merck Protocol MK-7902-003-01 - A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)
Summary: The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advance melanoma. The primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by Overall Survival (OS). For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
(Read more)
MSKCC - A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
Summary: Post PD1 & Post PD1/LAG3 Melanoma
Read more on NCI
(Read more)
SWOG 2101 - Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers – an immunoMATCH Pilot Study
Summary: HNSCC & Melanoma HEAVY PRETREATED
Condition/Disease: Melanoma
Read more on NCI
Melanoma (Advanced & Metastatic)
(Read more)
IMC-F106C-301 - IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)
Summary: HLA A2.01 treatment naieve advanced/metastatic melanoma (non-uveal): randomized to rela/nivo
Read more on NCI
(Read more)
IOV-GM1-201 - A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Summary: NSCLC and Melanoma Adoptive T cell Therapy
Read more on NCI
(Read more)
PF-08046031 - A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Summary: Antibody Drug Conjugate (ADC) n pretreated cutaneous melanoma
Read more on NCI
(Read more)
RP-202 - A Randomized, Phase 2/ 3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (RP2-202)
Summary: Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Read more on NCI
(Read more)
RP1-104 (Ignyte-3) - VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
Summary: Melanoma </= 2 lines max post CTLA4/PD1; 3 lines max if BRAF mutated
Read more on NCI
Molecular and Targeted Trials
(Read more)
BDTX-4933-101/TACRI - A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
Summary: BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase.
Read more on NCI
(Read more)
TBBO11818-101 - A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
Summary: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Read more on NCI
(Read more)
VS-7375-101 - A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors
Summary: This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Read more on NCI
Non Small Cell lung Cancer (NSCLC)
(Read more)
BDTX-4933-101/TACRI - A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
Summary: BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The study population for the Dose Escalation part of the study comprises adults with recurrent advanced/metastatic non-small cell lung cancer (NSCLC), Gastrointestinal (GI) cancers, and other solid tumors harboring KRAS, HRAS, NRAS, BRAF, and/or CRAF (Rapidly Accelerated Fibrosarcoma (RAF1)) mutations or alterations. A dose optimization part in adults with NSCLC may follow the dose escalation phase if the sponsor, in consultation with the safety review committee, decides it is necessary to further characterize the optimal dose. However, the study may also proceed directly to the expansion phase.
Read more on NCI
(Read more)
IIT 2102 - Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Summary: Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer
Read more on NCI
(Read more)
IOV-GM1-201 - A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Summary: NSCLC and Melanoma Adoptive T cell Therapy
Read more on NCI
(Read more)
TBBO11818-101 - A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
Summary: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Read more on NCI
(Read more)
VS-7375-101 - A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors
Summary: This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Read more on NCI
Ocular Melanoma
(Read more)
MCC21341 - A Phase II Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
Summary: The goal of this clinical research study is to find out if Cemiplimab plus Ziv-Aflibercept is safe and effective in treating your condition of metastatic (spread to other parts of your body) uveal melanoma. This research study will test the study drugs to see if the combination of Cemiplimab plus Ziv-Aflibercept can make tumors shrink or stop growing.
Read more on NCI
Oropharyngeal Cancer
(Read more)
IIT2023-14 - Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer
Summary: HNSCC
Read more on NCI
Pancreatic Cancer
(Read more)
Arcus Protocol AB680CSP00902 - A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies tumors
Summary: This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.
Condition/Disease: Pancreatic Cancer
Read more on NCI
(Read more)
NGM Bio Protocol 831-IO-101 - A Phase 1/1b dose escalation /expansion study of NGM831 as monotherapy and in combination with pembrolizumab in advanced or metastatic solid tumors
Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors.
Condition/Disease: Advanced Solid Tumors, Ovarian Cancer, Gastric Cancer, Melanoma - Metastatic Melanoma, Pancreatic Cancer, Phase I Clinical Trials, Head and Neck Cancer, Lung Cancer - Non-Small Cell, Renal Cell Carcinoma
Read more on NCI
(Read more)
TBBO11818-101 - A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers
Summary: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Read more on NCI
(Read more)
VS-7375-101 - A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors
Summary: This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Read more on NCI
Phase I Trials (Any Cancer)
(Read more)
AVZO-1418-1001 - A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors
Summary: This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy and potentially in combination therapy to patients with locally advanced or metastatic epithelial solid tumors.
Read more on NCI
(Read more)
CA2360001 - A Phase 1/2 Study of BMS-986482 as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
Summary: The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Read more on NCI
(Read more)
DB-1317-101 - A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants With Selected Advanced/Metastatic Solid Tumors
Summary: This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design and a BOIN design to identify the MTD or MAD of DB-1317; Phase 1b includes one randomized dose expansion cohort and two single-arm dose expansion cohorts to further evaluate the safety, tolerability and preliminary efficacy of DB-1317 in selected solid tumors and to identify optimal RP2D.
Read more on NCI
(Read more)
SMP-3124-101 - An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults With Advanced Solid Tumors
Summary: An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Read more on NCI
(Read more)
SNV4818-101 - A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors
Summary: This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.
Read more on NCI
Prostate
(Read more)
IIT2021-06 - Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Summary: Castration-Resistant Prostate Cancer
Read more on NCI
(Read more)
IIT2023-02-FREEDLAND-FAST-PRO - Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Summary: This is a Phase 2, randomized two-armed, multi-site study of 138 patients with metastatic castrate sensitive prostate adenocarcinoma. Patients will be randomized 1:1 to receive the fasting mimicking diet, or usual diet. All patients will receive standard of care treatment for their prostate cancer. The fasting mimicking diet will be consumed for 5 days per month for a total of 6 months and will be monitored by trained research dietitians. This study aims to examine the effects of a fasting mimicking diet (5 days per month eating L-Nutra products only for 6 months) vs. usual diet on response to cancer treatment of metastatic castrate sensitive prostate adenocarcinoma.
Read more on NCI
Advanced Cancer
(Read more)
TAPUR - Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
Summary: https://cdn.bfldr.com/KOIHB2Q3/as/39tsg65qhf362fx5fqfskp/TAPUR-Cohort-Report
Condition/Disease: Advanced Cancer
Read more on NCI
Bladder Cancer
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Cervical Cancer
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Colon Cancer
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Endometrial Cancer
(Read more)
GSK Protocol 212214 - A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors
Summary: This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. In addition, dostarlimab will be given as monotherapy and in combination with GSK6097608 and with GSK4428859A (EOS884448) in Japanese and Chinese participants. Drug name mentioned as GSK4428859A and EOS884448 are interchangeable for the same compound. In the rest of the document, the drug will be referred to as GSK4428859A (EOS884448).
Condition/Disease: Endometrial Cancer
Read more on NCI
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Esophageal Cancer
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Gastric Cancer
(Read more)
Astellas Protocol 8951-CL-0103 - A Phase 2 Study of IMAB362 as Monotherapy or in Combination with mFOLFOX6 in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression
Summary: The purpose of this study is to determine the Objective Response Rate (ORR) of zolbetuzimab as a single agent as assessed by an independent central reader. This study will also assess the ORR and Progression Free Survival (PFS) of zolbetuximab in combination with mFOLFOX6 (with or without Nivolumab) and in combination with pembrolizumab, assess the safety and tolerability, assess the effects on CLDN18.2 expression and assess the immunogenicity and immunomodulatory effects of zolbetuximab as a single agent and in combination with mFOLFOX6 (with or without Nivolumab) and in combination with pembrolizumab. This study will also evaluate the pharmacokinetics (PK) of zolbetuximab, oxaliplatin, fluorouracil (5-FU), and pembrolizumab, evaluate health-Related Quality of Life (HRQoL), evaluate the Disease Control Rate (DCR), Duration of Response (DOR), PFS of zolbetuximab as a single agent, in combination with mFOLFOX6 (with or without Nivolumab) and in combination with pembrolizumab based on both investigator and independent central reader assessment, assess Overall Survival (OS) of zolbetuximab as a single agent and in combination with pembrolizumab.
Condition/Disease: Gastric Cancer
Read more on NCI
(Read more)
mRNA-4157-P101 - Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (KEYNOTE-603)
Summary: Neo-Adjuvant Lung and Neo-Adjuvant Gastric Cancer
Condition/Disease: Gastric Cancer
Read more on NCI
(Read more)
NGM Bio Protocol 831-IO-101 - A Phase 1/1b dose escalation /expansion study of NGM831 as monotherapy and in combination with pembrolizumab in advanced or metastatic solid tumors
Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors.
Condition/Disease: Advanced Solid Tumors, Ovarian Cancer, Gastric Cancer, Melanoma - Metastatic Melanoma, Pancreatic Cancer, Phase I Clinical Trials, Head and Neck Cancer, Lung Cancer - Non-Small Cell, Renal Cell Carcinoma
Read more on NCI
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Head and Neck Cancer
(Read more)
NGM Bio Protocol 831-IO-101 - A Phase 1/1b dose escalation /expansion study of NGM831 as monotherapy and in combination with pembrolizumab in advanced or metastatic solid tumors
Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors.
Condition/Disease: Advanced Solid Tumors, Ovarian Cancer, Gastric Cancer, Melanoma - Metastatic Melanoma, Pancreatic Cancer, Phase I Clinical Trials, Head and Neck Cancer, Lung Cancer - Non-Small Cell, Renal Cell Carcinoma
Read more on NCI
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Hepatocellular Carcinoma
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Lung Cancer - Non-Small Cell
(Read more)
NGM Bio Protocol 831-IO-101 - A Phase 1/1b dose escalation /expansion study of NGM831 as monotherapy and in combination with pembrolizumab in advanced or metastatic solid tumors
Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors.
Condition/Disease: Advanced Solid Tumors, Ovarian Cancer, Gastric Cancer, Melanoma - Metastatic Melanoma, Pancreatic Cancer, Phase I Clinical Trials, Head and Neck Cancer, Lung Cancer - Non-Small Cell, Renal Cell Carcinoma
Read more on NCI
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Lung Cancer - Small Cell
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Melanoma - Metastatic Melanoma
(Read more)
NGM Bio Protocol 831-IO-101 - A Phase 1/1b dose escalation /expansion study of NGM831 as monotherapy and in combination with pembrolizumab in advanced or metastatic solid tumors
Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors.
Condition/Disease: Advanced Solid Tumors, Ovarian Cancer, Gastric Cancer, Melanoma - Metastatic Melanoma, Pancreatic Cancer, Phase I Clinical Trials, Head and Neck Cancer, Lung Cancer - Non-Small Cell, Renal Cell Carcinoma
Read more on NCI
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Merkel Cell Carcinoma
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Ovarian Cancer
(Read more)
NGM Bio Protocol 831-IO-101 - A Phase 1/1b dose escalation /expansion study of NGM831 as monotherapy and in combination with pembrolizumab in advanced or metastatic solid tumors
Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors.
Condition/Disease: Advanced Solid Tumors, Ovarian Cancer, Gastric Cancer, Melanoma - Metastatic Melanoma, Pancreatic Cancer, Phase I Clinical Trials, Head and Neck Cancer, Lung Cancer - Non-Small Cell, Renal Cell Carcinoma
Read more on NCI
Phase I Clinical Trials
(Read more)
AstraZeneca Protocol D8151C00001 - A phase II study to evaluate the safety, pharmaco kinetics, and clinical activity of AZD0171 in combination with durvalumab and chemotherapy in participants with locally advanced or metastatic solid tumors
Summary: The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
Condition/Disease: Advanced Solid Tumors, Phase I Clinical Trials
Read more on NCI
(Read more)
Bioatla Protocol BA3071-001 - A phase ½ study of BA3071 in combination with NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
Summary: The objective of this study is to assess safety and efficacy of BA3071 in solid tumors.
Condition/Disease: Advanced Solid Tumors, Phase I Clinical Trials
Read more on NCI
(Read more)
NGM Bio Protocol 831-IO-101 - A Phase 1/1b dose escalation /expansion study of NGM831 as monotherapy and in combination with pembrolizumab in advanced or metastatic solid tumors
Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors.
Condition/Disease: Advanced Solid Tumors, Ovarian Cancer, Gastric Cancer, Melanoma - Metastatic Melanoma, Pancreatic Cancer, Phase I Clinical Trials, Head and Neck Cancer, Lung Cancer - Non-Small Cell, Renal Cell Carcinoma
Read more on NCI
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
Renal Cell Carcinoma
(Read more)
NGM Bio Protocol 831-IO-101 - A Phase 1/1b dose escalation /expansion study of NGM831 as monotherapy and in combination with pembrolizumab in advanced or metastatic solid tumors
Summary: Study of NGM831 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors.
Condition/Disease: Advanced Solid Tumors, Ovarian Cancer, Gastric Cancer, Melanoma - Metastatic Melanoma, Pancreatic Cancer, Phase I Clinical Trials, Head and Neck Cancer, Lung Cancer - Non-Small Cell, Renal Cell Carcinoma
Read more on NCI
(Read more)
Treadwell Protocol TWT-101 - A First In-Human, Phase 1/2 Study of Cfi-402411, Hematopoietic Progenitor Kinase-1 (Hpk1) Inhibitor, As A Single Agent And In Combination With Pembrolizumab In Subjects With Advanced Solid Malignancies
Summary: The purpose of this study is to test the safety of an investigational drug called CFI-402411 alone and in combination with pembrolizumab and to study its effects in patients with advanced solid tumors who have progressed following previous therapies.
Condition/Disease: Advanced Solid Tumors, Gastric Cancer, Melanoma - Metastatic Melanoma, Merkel Cell Carcinoma, Esophageal Cancer, Colon Cancer, Bladder Cancer, Phase I Clinical Trials, Lung Cancer - Small Cell, Head and Neck Cancer, Endometrial Cancer, Cervical Cancer, Lung Cancer - Non-Small Cell, Hepatocellular Carcinoma, Renal Cell Carcinoma
Read more on NCI
